Trial
NCT01285310
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Amgen
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Apremilast 30 mg
Why stopped
Study is terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-08